Table 1 Clinical and demographic baseline characteristics of patients
Characteristic | n | % |
|---|---|---|
Total | 815 | 100 |
Sex | ||
Male/Female | 361/454 | 44.4/55.6 |
Age, y | ||
Mean age at first manifestation, years | 52.7 ± 20.0 | |
Mean age at diagnosis, years | 53.5 ± 19.8 | |
Early-onset MG (< 50 years) | 300 | 36.9 |
Decremental response | ||
Positive | 368 | 45.2 |
Negative | 446 | 54.8 |
Increment | ||
Positive | 6 | 0.7 |
Generalized MG at diagnosis | ||
Ocular MG | 215 | 26.3 |
Generalized MG | 589 | 72.7 |
MGFA class at diagnosis | ||
I (ocular) | 236 | 28.9 |
II | 309 | 37.9 |
III | 169 | 20.8 |
IV | 43 | 5.3 |
V | 25 | 3.0 |
Missing | 30 | 3.7 |
QMG-score at diagnosis, median ± IQR | 4.0 (2.0–8.0) | |
Antibody status | ||
Seronegative | 86 | 10.5 |
Seropositive | 714 | 87.6 |
Anti-AchR-ab | 641 | 89.9 |
Anti-MuSK-ab | 71 | 9.9 |
Anti-LRP4-ab | 2 | 0.3 |
Anti-Titin-ab | 156 | 21.8 |
Missing | 15 | 1.8 |
Thymectomy | 294 | 36.1 |
MRI or CT | ||
Thymoma-suspect | 98 | 12.0 |
Histology | ||
Thymoma | 158 | 19.4 |
First IST | ||
Azathioprine | 475 | 58.2 |
MMF | 46 | 5.6 |
Methotrexate | 41 | 5.0 |
Cyclosporine | 0 | 0 |
Mean corticosteroid dosage following diagnosis, mg | 15 ± 10 | |
Concomitant diseases | ||
Cardiovascular | 379 | 46.6 |
Arterial hypertension | 289 | 35.4 |
Heart failure (any cause) | 59 | 7.3 |
Aortic stenosis | 64 | 7.8 |
Cardiac arrythmia | 45 | 5.5 |
Other | 111 | 13.6 |
Pulmonary | 133 | 16.3 |
Chronic obstructive pulmonary disease | 74 | 9.1 |
Asthma | 28 | 3.5 |
Smoking | 89 | 10.9 |
Other | 23 | 2.8 |
Metabolic | 185 | 22.7 |
Diabetes mellitus (type 1 or 2) | 166 | 20.4 |
Hypercholesterolemia | 155 | 19.0 |
Other | 21 | 2.5 |
Gastrointestinal | 167 | 20.5 |
Celiac disease | 18 | 2.2 |
Gastroesophageal reflux disease | 91 | 11.1 |
Liver failure (any cause) | 15 | 18.4 |
Inflammatory bowel disease | 8 | 0.9 |
Other | 12 | 14.7 |
Malignancy other than thymoma | 91 | 11.2 |
Lung cancer | 22 | 2.7 |
Prostate cancer | 33 | 4.0 |
Breast cancer | 12 | 1.4 |
Other | 15 | 1.8 |
Autoimmune disease | 152 | 18.7 |
Hashimoto's disease | 44 | 5.3 |
Rheumatoid arthritis | 32 | 3.9 |
Psoriasis | 34 | 4.2 |
Multiple sclerosis | 3 | 0.3 |
Other | 22 | 2.7 |
Months of follow-up | 62.6 ± 73.3 |